Independent Expert

Harold E. Cohen, R.Ph., B.S., B.Ph.

Licensed Pharmacist and SVP, Publisher and Editor-in-Chief of U.S. Pharmacist

Harold E. Cohen, R.Ph., B.S., B.Ph., is a licensed pharmacist and SVP, Publisher and Editor-in-Chief of U.S. Pharmacist, the #1 read peer-reviewed journal subscribed by approximately 150,000 pharmacists. He completed his pharmacy and undergraduate studies at Rutgers University College of Arts and Sciences and his graduate work at Rutgers College of Pharmacy. Shortly after gradation he owned and operated two community pharmacies in New Jersey before entering the world of publishing.

Throughout his publishing career he has held the position of Publisher and/or Editor-in-Chief at several prestigious pharmacy journals including Drug Topics, Pharmacy Times, and Drug Store News. During his 40-year professional career, Harold has served on several national and international association committees and boards including the position of Chairman of the National Council of Prescription Drug Programs (NCPDP) twice.

He is a well-known speaker both here and abroad on topics relating to pharmacy and communications. He has also spoken at many pharmacy schools and association meetings on topics ranging from the business of pharmacy to the profession of pharmacy. As Publisher and Editor-in-Chief of U.S. Pharmacist, Harold is responsible for the business and editorial direction of this clinically-focused, peer-reviewed publication.

From this Expert

Posted On: Tuesday, 8/27/2013 11:03 pm
A: As with any trial and error testing, there must of course be a starting point and an endpoint where data can be accumulated and tested. While there is nothing in the literature citing specifically why 90 days has been established as a testing period, as in any testing protocol a baseline must be established and data collected over a period of time. This generally results in changes over a period of time during the testing period. But at some point there the law of diminishing returns sets in... Continue Reading
Posted On: Tuesday, 8/20/2013 12:44 am
A: Thankfully, given the volume of new chemical entities and drugs approved each year by the FDA, and despite extensive in vivo and in vitro testing, this is a relatively rare occurrence.  However, it does happen for a number of reasons. The Food and Drug Administration has strict guidelines for human new drug approvals (NDAs). Before a new chemical entity enters into one of four phases of in vivo clinical trials (see below), it undergoes extensive in vitro testing in the laboratory... Continue Reading
No Studies were Found.